financetom
Business
financetom
/
Business
/
Citigroup confirms departure of its head of risk data, analytics, reporting & tech
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Citigroup confirms departure of its head of risk data, analytics, reporting & tech
Jun 26, 2024 8:48 AM

NEW YORK/LONDON, June 26 (Reuters) -

Citigroup's ( C/PN ) head of risk data, analytics, reporting and tech

Peter Cai has left the bank, a spokesman confirmed.

The departure has been announced internally on Tuesday but

the bank has yet to appoint an executive to replace him.

Cai was recently more focused on risk data analytics and

reporting, and responsibility for data remediation was shifted

in early 2023 from his division to a specific new team,

according to one source with knowledge of the matter.

Cai did not reply to messages to his Linkedin profile

asking for comment. The bank, that declined to comment beyond

confirming the departure of Cai, a former Barclays executive and

Carnegie Mellon professor, who was at Citigroup ( C/PN ) since 2019.

Last week, regulators increased the level of concern

with Citigroup's ( C/PN ) resolution plan, classifying its so-called

"living will" as deficient.

In a letter to Citi, regulators said weaknesses in its data

and controls contributed to inaccurate calculations of the

liquidity and capital needed to unwind derivatives positions.

They also asked for "independent confirmation" by next year that

the issues are addressed.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Wellington-Altus Announces $400 Mln Investment From Kelso & Company
BRIEF-Wellington-Altus Announces $400 Mln Investment From Kelso & Company
Oct 20, 2025
Oct 20 (Reuters) - Wellington-Altus Financial Inc: * WELLINGTON-ALTUS ANNOUNCES NEARLY $400M STRATEGIC MINORITY INVESTMENT FROM LEADING PRIVATE EQUITY FIRM KELSO & COMPANY, CONFIRMING $1.5B+ VALUATION * WELLINGTON-ALTUS FINANCIAL: UPON COMPLETION, KELSO TO ACQUIRE 25% MINORITY STAKE IN CO IN COMMON EQUITY TRANSACTION Source text: ...
Cumberland to Invest in RedHill Biopharma's Talicia Business
Cumberland to Invest in RedHill Biopharma's Talicia Business
Oct 20, 2025
11:36 AM EDT, 10/20/2025 (MT Newswires) -- RedHill Biopharma ( RDHL ) said Monday Cumberland Pharmaceuticals (CPIX) will invest $4 million for a 30% ownership stake in RedHill's global Talicia business. The companies will share in the financial performance and operational support for the Talicia brand, RedHill said. Talicia is approved for the treatment of helicobacter pylori infection. RedHill also...
Factbox-Trump's tariffs: What's in effect and what could be in store?
Factbox-Trump's tariffs: What's in effect and what could be in store?
Oct 20, 2025
WASHINGTON (Reuters) -U.S. President Donald Trump has launched a global trade war with an array of tariffs that target individual products and countries.  Trump has set a baseline tariff of 10% on all imports to the United States, as well as additional duties on certain products or countries.  Here is a list of targeted tariffs he has implemented or threatened...
Immatics Says Anzu-cel Shows 'Strong' Anti-Tumor Activity in Uveal Melanoma Trial; Shares Rise
Immatics Says Anzu-cel Shows 'Strong' Anti-Tumor Activity in Uveal Melanoma Trial; Shares Rise
Oct 20, 2025
11:34 AM EDT, 10/20/2025 (MT Newswires) -- Immatics ( IMTX ) said Monday that updated data from 16 patients with metastatic uveal melanoma treated with anzu-cel PRAME cell therapy showed continued strong anti-tumor activity and durability of response. The company said data from the ongoing phase 1b trial evaluating anzu-cel show that the confirmed objective response rate was 67%, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved